6KO1

The crystal structue of PDE10A complexed with 2d

Summary for 6KO1

• Entry DOI: 10.2210/pdb6ko1/pdb
• Descriptor: cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, ZINC ION, MAGNESIUM ION, ... (5 entities in total)
• Functional Keywords: pde10a inhibitor, hydrolase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 75593.22

Authors

Huang, Y.-Y.,Yu, Y.F.,Zhang, C.,Guo, L.,Wu, D.,Luo, H.-B. (deposition date: 2019-08-07, release date: 2020-04-01, Last modification date: 2023-11-22)

Primary citation

Yu, Y.F.,Zhang, C.,Huang, Y.Y.,Zhang, S.,Zhou, Q.,Li, X.,Lai, Z.,Li, Z.,Gao, Y.,Wu, Y.,Guo, L.,Wu, D.,Luo, H.B.
Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors.
Acs Chem Neurosci, 11:1058-1071, 2020

PubMed Abstract: Phosphodiesterase 10 (PDE10) inhibitors have received much attention as promising therapeutic agents for central nervous system (CNS) disorders such as schizophrenia and Huntington's disease. Recently, a hit compound with a novel chromone scaffold has shown moderate inhibitory activity against PDE10A (IC = 500 nM). Hit-to-lead optimization has resulted in compound with an improved inhibitory activity (IC = 6.5 nM), remarkable selectivity (>95-fold over other PDEs), and good metabolic stability (RLM = 105 min) by using an integrated strategy (molecular modeling, chemical synthesis, bioassay, and cocrystal structure). The cocrystal structural information provides insights into the binding pattern of in the PDE10A catalytic domain to highlight the key role of the halogen and hydrogen bonds toward Tyr524 and Tyr693, respectively, thereby resulting in high selectivity against other PDEs. These new observations are of benefit for the rational design of the next generation PDE10 inhibitors for CNS disorders.

PubMed: 32105440
DOI: 10.1021/acschemneuro.0c00024

Experimental method

X-RAY DIFFRACTION (2.7 Å)